Fresenius Medical Care
About: Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.
Employees: 119,845
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
97% more call options, than puts
Call options by funds: $1.62M | Put options by funds: $822K
44% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 45
0.98% less ownership
Funds ownership: 11.66% [Q1] → 10.68% (-0.98%) [Q2]
3% less funds holding
Funds holding: 169 [Q1] → 164 (-5) [Q2]
9% less capital invested
Capital invested by funds: $660M [Q1] → $598M (-$61.9M) [Q2]
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Truist Securities David Macdonald 76% 1-year accuracy 31 / 41 met price target | 15%upside $23 | Hold Maintained | 7 Oct 2024 |
Truist Securities David Macdonald 76% 1-year accuracy 31 / 41 met price target | 10%upside $22 | Hold Maintained | 31 Jul 2024 |
Financial journalist opinion
Based on 7 articles about FMS published over the past 30 days